172 related articles for article (PubMed ID: 37982732)
1. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
[No Abstract] [Full Text] [Related]
2. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
González Barca E
Front Immunol; 2022; 13():909008. PubMed ID: 35928819
[TBL] [Abstract][Full Text] [Related]
3. Epcoritamab: First Approval.
Frampton JE
Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
Polgarova K; Trneny M
Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N
Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363
[TBL] [Abstract][Full Text] [Related]
6. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
Liu X; Zhao J; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
[TBL] [Abstract][Full Text] [Related]
7. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
[TBL] [Abstract][Full Text] [Related]
8. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.
Cassanello G; Luna de Abia A; Falchi L
Oncoimmunology; 2024; 13(1):2321648. PubMed ID: 38445082
[TBL] [Abstract][Full Text] [Related]
9. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Dickinson MJ; Carlo-Stella C; Morschhauser F; Bachy E; Corradini P; Iacoboni G; Khan C; Wróbel T; Offner F; Trněný M; Wu SJ; Cartron G; Hertzberg M; Sureda A; Perez-Callejo D; Lundberg L; Relf J; Dixon M; Clark E; Humphrey K; Hutchings M
N Engl J Med; 2022 Dec; 387(24):2220-2231. PubMed ID: 36507690
[TBL] [Abstract][Full Text] [Related]
10. Update on bi-specific monoclonal antibodies for blood cancers.
Shouse G
Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
[TBL] [Abstract][Full Text] [Related]
12. Glofitamab: First Approval.
Shirley M
Drugs; 2023 Jul; 83(10):935-941. PubMed ID: 37285013
[TBL] [Abstract][Full Text] [Related]
13. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
Song YQ; Zhang HL; Huang HQ; Zhang QY; Jing HM; Wang C; Wu C; Li DH; Dai Y; Humphrey K; Zhu J
Haematologica; 2024 Apr; 109(4):1269-1273. PubMed ID: 37855035
[No Abstract] [Full Text] [Related]
14. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
Yamaguchi M
Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
[TBL] [Abstract][Full Text] [Related]
15. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies in indolent B-cell lymphomas.
Radhakrishnan VS; Davies AJ
Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
[TBL] [Abstract][Full Text] [Related]
17. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
19. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
Zinzani PL; Minotti G
J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
